August 25, 2026

Jazz-Zymeworks Ziihera FDA Approval HER2+ GEA, Intismeran $1B 2031 Forecast, Roche HM17321 Positioning, Regenxbio RGX-121 Hold

Jazz-Zymeworks Ziihera FDA approval for first-line HER2+ GEA. Intismeran forecast >$1B by 2031. Roche HM17321 positioning. Regenxbio RGX-121 clinical hold.

4 stories · Covering regulatory, industry

Editor's Note

Tuesday's biotech news is anchored on the Jazz Pharmaceuticals (NASDAQ: JAZZ) and Zymeworks (NASDAQ: ZYME) Ziihera (zanidatamab-hrii, an anti-HER2 bispecific antibody) FDA approval on the August 25, 2026 PDUFA target action date for first-line treatment of adult patients with HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma; the FDA approved two zanidatamab-hrii regimens (with and without tislelizumab plus chemotherapy) based on Phase 3 HERIZON-GEA-01 data showing median overall survival of more than two years. The approval triggers a $250 million milestone payment from Jazz to Zymeworks, with Zymeworks remaining eligible for up to $1.3 billion in additional milestones plus tiered royalties of up to 20% on net sales. Sell-side analysts published Tuesday projected Merck (NYSE: MRK) and Moderna (NASDAQ: MRNA) intismeran autogene sales trajectories exceeding $1 billion by 2031 following the August 19 INTerpath-001 Phase 3 melanoma win. Follow-through commentary on the August 24 Roche (SIX: ROG) and Hanmi Pharm HM17321 UCN2 obesity licensing deal positioned Roche as targeting a top-three obesity commercial position behind Eli Lilly and Novo Nordisk, with the HM17321 CRFR2 receptor agonist peptide mechanism combined with Roche's CT-388 dual GIP/GLP-1 agonist (from the Carmot acquisition) providing a multi-mechanism obesity pipeline. And Regenxbio (NASDAQ: RGNX) shares fell 25% to $8.05 Tuesday after the FDA placed a clinical hold on RGX-121 gene therapy for Mucopolysaccharidosis type II (MPS II).

Regulatory

Jazz Pharmaceuticals (NASDAQ: JAZZ) and Zymeworks (NASDAQ: ZYME) Received FDA Approval Tuesday August 25, 2026 for Ziihera (Zanidatamab-Hrii, an Anti-HER2 Bispecific Monoclonal Antibody) in Combination Regimens (With and Without Tislelizumab Plus Chemotherapy) for First-Line Treatment of Adult Patients With HER2-Positive (IHC 3+) Unresectable Locally Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (GEA); The Approval Was Based on the Phase 3 HERIZON-GEA-01 Trial Documenting Median Overall Survival of More Than Two Years, and Triggers a $250 Million Milestone Payment From Jazz to Zymeworks With Zymeworks Remaining Eligible for Up to $1.3 Billion in Additional Milestones Plus Tiered Royalties of Up to 20% on Net Sales

Jazz Pharmaceuticals (NASDAQ: JAZZ) and Zymeworks (NASDAQ: ZYME) received FDA approval Tuesday August 25, 2026 for Ziihera (zanidatamab-hrii, an anti-HER2 bispecific monoclonal antibody) in combination regimens for first-line treatment of adult patients with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). Approved regimens: Ziihera with chemotherapy (fluoropyrimidine and platinum), and Ziihera with tislelizumab (BeiGene's anti-PD-1 monoclonal antibody) plus chemotherapy. Trial basis: Phase 3 HERIZON-GEA-01 documented median overall survival of more than two years. Ziihera mechanism: zanidatamab-hrii is a bispecific antibody that binds two distinct epitopes on HER2 simultaneously, producing higher-affinity target engagement, receptor clustering, and immune-mediated tumor cell killing versus conventional monospecific anti-HER2 antibodies. The approval triggers a $250 million milestone payment from Jazz to Zymeworks, with Zymeworks remaining eligible for up to $1.3 billion in additional milestones plus tiered royalties of up to 20% on net sales. Jazz expects to launch Ziihera commercially in the US in this indication. The approval extends the Ziihera commercial franchise beyond its earlier accelerated approval in biliary tract cancer to a substantially larger commercial indication in HER2-positive GEA. GEA is a globally common cancer with roughly 22,000 US cases per year and substantially higher incidence in Asia; roughly 15-25% of GEA cases express HER2, defining the addressable population. The result is a positive readout for the bispecific antibody modality more broadly.

#jazz-pharmaceuticals #jazz #zymeworks #zyme #ziihera #zanidatamab #bispecific-antibody #anti-her2 #gastroesophageal-adenocarcinoma #gea #herizon-gea-01 #tislelizumab #beigene #250-million-milestone #1-3-billion-additional-milestones #20-percent-royalty

Industry

Sell-Side Analysts Published Tuesday August 25, 2026 Projections That Merck (NYSE: MRK) and Moderna (NASDAQ: MRNA) Intismeran Autogene (V940 / mRNA-4157, the Individualized Neoantigen Therapy That Encodes Up to 34 Tumor-Specific Neoantigen Peptides From Each Individual Patient's Tumor Mutation Signature Delivered as a Lipid Nanoparticle mRNA Injection) Will Exceed $1 Billion in Annual Sales by 2031 Following the August 19 Positive Phase 3 INTerpath-001 Melanoma Readout That Met the Primary Endpoint of Recurrence-Free Survival and Key Secondary Endpoint of Distant Metastasis-Free Survival in Adults With Completely Resected Stage IIB-IV Melanoma; The Sales Trajectory Assumes Approvals Across Additional Adjuvant Indications Currently in Phase 3 Development Including Non-Small-Cell Lung Cancer, Renal Cell Carcinoma, and Cutaneous Squamous Cell Carcinoma

Sell-side analysts published Tuesday August 25, 2026 projections that Merck (NYSE: MRK) and Moderna (NASDAQ: MRNA) intismeran autogene (V940 / mRNA-4157) will exceed $1 billion in annual sales by 2031 following the August 19 positive Phase 3 INTerpath-001 melanoma readout. Product context: intismeran autogene is an individualized neoantigen therapy that uses each individual patient's tumor mutation signature to design a personalized mRNA vaccine encoding up to 34 tumor-specific neoantigen peptides. The mRNA is delivered as a lipid nanoparticle injection; cells at the injection site translate the mRNA into the neoantigen peptides, which are then presented to the immune system to generate a targeted T-cell response against the patient's tumor. The INTerpath-001 Phase 3 trial met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival in adults with completely resected Stage IIB-IV cutaneous melanoma. The $1+ billion 2031 sales trajectory assumes approvals across additional adjuvant indications currently in Phase 3 development including non-small-cell lung cancer (INTerpath-002), renal cell carcinoma (INTerpath-003), and cutaneous squamous cell carcinoma (INTerpath-005). Manufacturing scale-up remains a substantial commercial constraint because each patient dose requires an individualized manufacturing run driven by that patient's tumor sequence, unlike traditional off-the-shelf drugs; Moderna is investing in automated manufacturing infrastructure to support the projected launch volumes. The sales trajectory reset materially resets investor expectations about the personalized neoantigen therapy modality that had traded largely on Phase 2 data until the August 19 confirmatory Phase 3 result.

#merck #mrk #moderna #mrna #intismeran-autogene #v940 #mrna-4157 #individualized-neoantigen-therapy #1-billion-2031 #sales-forecast #interpath-001 #interpath-002 #interpath-003 #cancer-vaccine #personalized-medicine

Industry

Follow-Through Analyst Commentary Tuesday August 25, 2026 on the Monday Roche (SIX: ROG) and Hanmi Pharm HM17321 Urocortin-2 (UCN2) Obesity Licensing Deal ($190 Million Upfront, Up to $2.3 Billion in Milestones, Plus Tiered Royalties) Positioned Roche as Now Targeting a Top-Three Global Obesity Commercial Position Behind Eli Lilly (Zepbound, Mounjaro, Foundayo, and Upcoming Retatrutide) and Novo Nordisk (Wegovy, Ozempic, Wegovy Pill, Wegovy HD, CagriSema Under Review); The HM17321 CRFR2 Receptor Agonist Peptide Mechanism Combined With Roche's Existing CT-388 Dual GIP/GLP-1 Receptor Agonist (Acquired in the 2023 Carmot Therapeutics Acquisition, in Phase 2 for Obesity and Type 2 Diabetes) and the Emerging Roche Obesity Pipeline Provides a Multi-Mechanism Portfolio to Compete Across Efficacy and Muscle-Preservation Positioning

Follow-through analyst commentary Tuesday August 25, 2026 on the Monday Roche (SIX: ROG) and Hanmi Pharm HM17321 urocortin-2 (UCN2) obesity licensing deal positioned Roche as now targeting a top-three global obesity commercial position behind Eli Lilly (Zepbound, Mounjaro, Foundayo, and upcoming retatrutide) and Novo Nordisk (Wegovy, Ozempic, Wegovy Pill, Wegovy HD, CagriSema under review). Deal recap: $190 million upfront, up to $2.3 billion in milestones, plus tiered royalties; Genentech gets global rights excluding South Korea. HM17321 mechanism: a proprietary urocortin-2 (UCN2) analog peptide that selectively activates the corticotropin-releasing factor 2 receptor (CRFR2), a mechanism distinct from the incretin pathway (GLP-1, GIP) that anchors every currently-approved obesity drug. Roche obesity portfolio positioning: HM17321 combines with Roche's existing CT-388 (a dual GIP/GLP-1 receptor agonist acquired in the December 2023 Carmot Therapeutics acquisition for $2.7 billion, currently in Phase 2 for obesity and type 2 diabetes) and the emerging Roche obesity pipeline including RG7500 orforglipron precursor and other early-stage assets. The multi-mechanism portfolio provides a differentiated commercial positioning to compete across weight-loss efficacy (Roche's incretin agonist candidates match Lilly and Novo) and muscle-preservation (HM17321's differentiated UCN2 mechanism designed for lean mass preservation). Roche's obesity ambition contrasts with prior investor skepticism about its late-cycle entry into the category; Tuesday's analyst commentary suggests the multi-mechanism strategy could position Roche credibly for 2028-2030 commercial launches assuming pipeline programs advance to registration.

#roche #rog #hanmi-pharm #hm17321 #ucn2-analog #obesity-positioning #top-three-target #ct-388 #carmot-therapeutics #eli-lilly #novo-nordisk #muscle-preservation #multi-mechanism-portfolio #genentech

Regulatory

Regenxbio (NASDAQ: RGNX) Shares Fell Approximately 25% to $8.05 Tuesday August 25, 2026 After the FDA Placed a Clinical Hold on the RGX-121 Gene Therapy Program for the Treatment of Mucopolysaccharidosis Type II (MPS II, Also Known as Hunter Syndrome, a Rare X-Linked Lysosomal Storage Disease Caused by Iduronate-2-Sulfatase (IDS) Deficiency That Results in Accumulation of Glycosaminoglycans in Multiple Tissues Including the Central Nervous System, With Progressive Cognitive Decline, Skeletal Abnormalities, and Cardiac and Respiratory Involvement in the Severe Neuronopathic Form); RGX-121 Is an AAV Gene Therapy Delivering an IDS-Encoding Transgene Via Intracerebroventricular Administration Designed to Address the Neurocognitive Manifestations That the Currently-Approved Enzyme Replacement Therapy Elaprase (Idursulfase) Does Not Reach

Regenxbio (NASDAQ: RGNX) shares fell approximately 25% to $8.05 Tuesday August 25, 2026 after the FDA placed a clinical hold on the RGX-121 gene therapy program for the treatment of Mucopolysaccharidosis type II (MPS II, also known as Hunter Syndrome). Disease context: MPS II is a rare X-linked lysosomal storage disease affecting approximately 1 in 100,000-170,000 male births globally, caused by iduronate-2-sulfatase (IDS) enzyme deficiency that results in accumulation of glycosaminoglycans (GAGs) in multiple tissues including the central nervous system. Clinical manifestations include progressive cognitive decline, skeletal abnormalities, cardiac and respiratory involvement, and reduced life expectancy in the severe neuronopathic form (approximately two-thirds of patients). RGX-121 mechanism: an AAV (adeno-associated virus) gene therapy delivering an IDS-encoding transgene via intracerebroventricular administration designed to establish stable IDS expression in the central nervous system, addressing the neurocognitive manifestations that the currently-approved enzyme replacement therapy Elaprase (idursulfase, Takeda) does not reach because Elaprase administered intravenously does not cross the blood-brain barrier. Specific reasons for the FDA clinical hold have not been publicly disclosed by Regenxbio; details are expected in subsequent regulatory correspondence. The clinical hold delays but does not necessarily preclude the RGX-121 development pathway. Regenxbio's broader pipeline includes RGX-202 for Duchenne muscular dystrophy in Phase 3, RGX-314 for wet AMD in Phase 3, and multiple additional gene therapy candidates.

#regenxbio #rgnx #rgx-121 #mucopolysaccharidosis-type-ii #hunter-syndrome #mps-ii #aav-gene-therapy #iduronate-2-sulfatase #ids-deficiency #fda-clinical-hold #25-percent-stock-decline #elaprase-comparison #central-nervous-system